Connor, Clark & Lunn Investment Management Ltd. Heron Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$2.25 - $4.67 $371,790 - $771,670	-165,240 Reduced 72.28%	63,371 $158,000
Q3 2022 Nov 10, 2022	BUY	$2.66 - $5.37 $608,105 - $1.23 Million	228,611 New	228,611 $965,000
Q2 2022 Aug 05, 2022	SELL	$2.3 - $6.29 $289,643 - $792,112	-125,932 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.63 - $9.94 $583,065 - $1.25 Million	125,932 New	125,932 $720,000

Others Institutions Holding HRTX

# of Institutions

180

Shares Held

121M

Call Options Held

80.4K

Put Options Held

94.9K

Rubric Capital Management LP New York, NY

26.7M
Shares

$29.9 Million
1.48% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

8.85M
Shares

$9.91 Million
0.03% of portfolio
Vanguard Group Inc Valley Forge, PA

8.72M
Shares

$9.77 Million
0.0% of portfolio
Black Rock Inc. New York, NY

8.33M
Shares

$9.32 Million
0.0% of portfolio
Velan Capital Investment Management LP Alpharetta, GA

6.99M
Shares

$7.83 Million
28.8% of portfolio

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $133M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account